Dossier assessment
Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Indication of considerable added benefit of vemurafenib in advanced melanoma
Advantages for overall survival, but also disadvantages in the form of side effects
Additional information
IQWiG health information
Federal Joint Committee (G-BA)
2012-09-06 A G-BA decision was published.
Project details
- Project no.
- A12-08
- Commission
- Commission awarded on 21.02.2012 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair, Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed